Which option would you pick that you think makes sense.
Which option would you pick that you think makes sense.
Option 1 - Drill 3 Kubs now and then the next 10 when you get the financing which could take who knows how long or
Option 2 - Wait for who knows how long to drill the 13 wells.
I pick Option 1 just to get the wells done and money comes in right away then this to me shows a positive and might make it easier to complete the financing. This is just a bullshit excuse which may mean they do not have the money to drill now.
Treaty Energy Corporation (TECO) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Recognizing a Game-Changer in Financial Wellness Vanessa Hering's name isn't just getting thrown around for no reason, folks. She's the client success officer at Beyond Finance, a heavyweight in the financial wellness arena, and she's just snagged the 2026 Herizon Award. This ain't some run-of-the-mill accolade; it acknowledges the profound changes she's spearheaded in...
Continue Reading
From Local Fixture to National Recognition Ravi Bhalla, owner of PostalAnnex #16006 in Calabasas, CA, takes home the Crystal Award at Annex Brands' 2026 National Convention in Vegas. And let me tell you, this isn't just some shiny trophy to stuff in a display case. This is major. Shattering Sales Goals What's the big kerfuffle over? It's this: Bhalla cracked the $5...
Continue Reading
What's Brewing with Lumentum and Marvell? There's no denying the chatter on Wall Street when there's a potential shake-up, especially with a big merger at stake. We're staring down the barrel of an investigation concerning Lumentum Holdings Inc. (NASDAQ: LITE) and Marvell Technology, Inc.'s deal. The M&A Class Action Firm, helmed by Juan Monteverde, is the name leading...
Continue Reading
A Rollercoaster Quarter for Autohome Diving right into Autohome's latest financial results, and boy, it's not the cheeriest news we've heard. For Q3 2026, the famed online auto hub's net revenue is down to RMB1,315.0 million from RMB1,778.1 million a year prior. That's a hefty slide in any trader's book. More so, net income attributable to the company tumbled from...
Continue Reading
Breaking New Ground in Thyroid Eye Disease Treatment If there's one thing that keeps the biopharma world on its toes, it's the relentless pursuit of groundbreaking treatments. And folks, let me tell you, the latest tie-up between Minghui Pharmaceutical and ASKA Pharmaceutical has struck a chord. This union with MHB018A at its core might be one of those watershed moments...
Continue Reading
No More Drills: The TensionLock Game-Changer Now, here's something my back has been waiting for—REGAL Estate's QuickInsta® TensionLock Cellular Shades could be the answer for every DIY warrior who's tired of wrestling with power tools just to get some privacy. This Georgia-based company's newest addition skips the screws, drills, and headaches, letting you install...
Continue Reading
What's Really Going On with BWIN, LFCR, and PCRX? Everyone talks about when there's smoke, there's fire. But in this case, it’s hard not to wonder if we're standing knee-deep in burning embers, or just a dusty old campfire. Halper Sadeh LLC is ringing the alarm bells for Baldwin Group, Lifecore Biomedical, and Pacira BioSciences, the trio tagged under NASDAQ: BWIN,...
Continue Reading
A New Chapter in the AI Narrative Take a seat, folks, because we're watching AI swing from showy tech to something as plain as plumbing infrastructure. Imagine models that once cost bundles per token now going for peanuts. We're talking a nosedive from $37.50 to a mere 18 cents. It’s a seismic shift, steering the conversation from 'Are they the best models?' to 'How...
Continue Reading
The Evolution of CVS Health Walking through CVS Health's latest move feels like watching a torch split into two flames, each set to shine its own light in the healthcare industry. This behemoth of pharmacy and healthcare solutions is gearing up to divide into two independent, publicly traded entities by the first half of 2028. A decision not made lightly, this separation...
Continue Reading
Revolutionizing Automotive Sales Analytics Look at Clarivoy, shaking up the auto sales world with a beefed-up platform tailored for the folks who've been craving some straight-shooting insights. We're talking no more guessing games with your marketing dollars. As of November 2, 2026, Clarivoy's latest iteration leaps forward, sporting tools built to dissect every nook and...
Continue Reading
Top 5 Most Recently Viewed Articles
SEATOM's Selection for NATO's Accelerator Programme Today, SEATOM announced a significant milestone as it was chosen to participate in the NATO Defence Innovation Accelerator for the North Atlantic (DIANA) 2026 Challenge Programme. This prestigious selection underscores SEATOM's innovative approach to developing nuclear technology tailored for maritime and extreme...
Continue Reading
OpenAI Completes a Major Acquisition OpenAI has recently wrapped up a remarkable deal by acquiring Jony Ive's AI hardware startup, io Products, for a staggering $6.5 billion. This acquisition brings the design genius, renowned for his work at a major tech giant, into OpenAI's fold to help create a new generation of smart devices. Key Developments Post-Acquisition The...
Continue Reading
Opportunities for KinderCare Investors Robbins Geller Rudman & Dowd LLP has announced a significant opportunity for investors of KinderCare Learning Companies, Inc. (NYSE: KLC) who have experienced substantial losses. This is a pivotal moment for shareholders as they can now seek to lead a class action lawsuit against the company. Understanding the Class Action Lawsuit...
Continue Reading
Growth of Baltic Horizon Fund's NAV in May 2025 The Baltic Horizon Fund reported an increase in its net asset value (NAV) per unit, which rose to EUR 0.6757 at the close of May 2025. This figure represents a slight gain from the NAV of EUR 0.6740 recorded at the end of April 2025. The fund's overall net asset value reached EUR 97.0 million, up from EUR 96.8 million in the...
Continue Reading
Autolus Therapeutics Showcases CARLYSLE Trial Results Autolus Therapeutics plc (Nasdaq: AUTL), a biopharmaceutical leader in developing innovative T cell therapies, recently showcased promising preliminary data from the CARLYSLE trial, which focuses on severe refractory systemic lupus erythematosus (srSLE). The data were presented during a special session at a leading...
Continue Reading